Rate of all infection for ustekinumab versus standard oral systemic therapeutic agents (acitretin, cyclosporine, or methotrexate) in the management of psoriasis: A report from the RADAR (Research on Adverse Drug events And Reports) project - 11/08/17
Regine J. Mathieu, BS, Department of Dermatology, Feinberg School of Medicine, Northwestern University; Shivani Reddy, University of Illinois at Chicago College of Medicine; Emily Lund, MD, Department of Dermatology, Feinberg School of Medicine, Northwestern University; Stephanie M. Rangel, PhD, Department of Dermatology, Feinberg School of Medicine, Northwestern University; Dennis P. West, PhD, Department of Dermatology, Feinberg School of Medicine, Northwestern University; Beatrice Nardone, MD, Department of Dermatology, Feinberg School of Medicine, Northwestern University
Le texte complet de cet article est disponible en PDF. Commercial support: None identified. |
Vol 76 - N° 6S1
P. AB214 - juin 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?